Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 152,831 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Condition Clear all
Not listed Not applicable Interventional

Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a "Drug Holiday" From Bisphosphonates

NCT02575157
View directory record Official record
Conditions
Osteoporosis
Interventions
No intervention
Other
Lead sponsor
National Bone Health Alliance
Other
Eligibility
50 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder

NCT05103657
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
BI 1358894, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
37
States / cities
Little Rock, Arkansas • Glendale, California • Long Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols

NCT00884312
View directory record Official record
Conditions
Multiple Myeloma, Solid Tumors
Interventions
Carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
21
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 23, 2026, 2:50 PM EDT
Recruiting Not applicable Interventional

Reward Sensitivity Digital Intervention for Suicide Risk

NCT07661901
View directory record Official record
Conditions
Suicidal Ideation, Suicidal, Suicidal Thoughts, Digital Health Intervention, Reward Sensitivity, Anhedonia
Interventions
Suicide prevention treatment
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
13 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Not applicable Interventional

Qigong Therapy For Heart Device Patients

NCT00027001
View directory record Official record
Conditions
Depressive Disorder, Cardiac Diseases
Interventions
Aerobic and Resistance Exercises, Qigong
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

NCT00630812
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
inhaled mannitol, Placebo comparator
Drug
Lead sponsor
Syntara
Industry
Eligibility
6 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
28
States / cities
Tucson, Arizona • Hartford, Connecticut • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tumescent Antibiotic Delivery Pharmacokinetics

NCT01046981
View directory record Official record
Conditions
Prevention of Surgical Site Infections
Interventions
Tumescent Antibiotic Delivery of cefazolin with or without metronidazole, Intravenous Antibiotic Delivery
Procedure
Lead sponsor
Klein, Jeffrey A., M.D.
Individual
Eligibility
21 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Juan Capistrano, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2011 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

NCT03137381
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, CTP-543 matching placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
13
States / cities
Irvine, California • Rancho Mirage, California • Redwood City, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 23, 2026, 2:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Indoor Air Quality for Black Adults With Uncontrolled Asthma

NCT05685381
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Beacon, New York • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

NCT06742281
View directory record Official record
Conditions
COVID-19
Interventions
CVXGA (CVXGA50), COMIRNATY®
Biological
Lead sponsor
CyanVac LLC
Industry
Eligibility
18 Years to 100 Years
Enrollment
432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
55
States / cities
Anniston, Alabama • Phoenix, Arizona • Chula Vista, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 2:50 PM EDT
Not listed Phase 2 Interventional

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

NCT04163419
View directory record Official record
Conditions
Schwannomatosis, Pain
Interventions
Tanezumab, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 23, 2026, 2:50 PM EDT
Recruiting Phase 2 Interventional

A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

NCT07533019
View directory record Official record
Conditions
Vitiligo, Non-Segmental Vitiligo (NSV)
Interventions
LY4005130, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Fremont, California • Northridge, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

OK432 (Picibanil) in the Treatment of Lymphatic Malformations

NCT03427619
View directory record Official record
Conditions
Lymphatic Malformations
Interventions
OK432
Drug
Lead sponsor
Richard JH Smith
Other
Eligibility
6 Months to 17 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2018
U.S. locations
14
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Botulin-A Toxin Instillations and Overactive Bladder

NCT00583219
View directory record Official record
Conditions
Overactive Bladder, Detrusor Instability, Detrusor Hyperreflexia
Interventions
Botulinum-A toxin, Dimethyl sulfoxide (DMSO)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 23, 2026, 2:50 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients

NCT06409819
View directory record Official record
Conditions
Urinary Tract Infection, Recurrent
Interventions
phage therapy, control
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 23, 2026, 2:50 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

NCT06964230
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
T3D-959, Placebo Comparator
Drug · Other
Lead sponsor
T3D Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib

NCT01725230
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib, Rosuvastatin, Simvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 23, 2026, 2:50 PM EDT
Enrolling by invitation Phase 3 Interventional

Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA

NCT04360265
View directory record Official record
Conditions
Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A
Interventions
No Investigational Product, Adjuvant Immunomodulatory (IM) Therapy
Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00456365
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
pravastatin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 22 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 1 Interventional

Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

NCT01836367
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate 0.015%
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 23, 2026, 2:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Deployment Health in Regular Military Women

NCT01692067
View directory record Official record
Conditions
Military Physical and Sexual Trauma, Combat Trauma, PTSD, TBI
Interventions
Not listed
Lead sponsor
Iowa City Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 60 Years
Enrollment
871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 23, 2026, 2:50 PM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

NCT01273467
View directory record Official record
Conditions
Stroke, Ischemia, Infarction
Interventions
CNTO 0007 or placebo (Stage A), CNTO 0007 or placebo (Stage B)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 23, 2026, 2:50 PM EDT
Not listed Not applicable Interventional

PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System

NCT06054867
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
Robotic Waterjet Treatment
Device
Lead sponsor
PROCEPT BioRobotics
Industry
Eligibility
40 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Glenview, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 23, 2026, 2:50 PM EDT
Recruiting Not applicable Interventional

Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients

NCT06138067
View directory record Official record
Conditions
Prostate Cancer, Kidney Cancer
Interventions
High intensity approach, Low intensity approach
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Chambersburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 23, 2026, 2:50 PM EDT